

G
F
E
D
C
B
A
SC 3 mg/kg
Group 4
IV 5 mg/kg
IV 3 mg/kg
Group 3
IV 1 mg/kg
IV 0.3 mg/kg
Group 2
IV 0.03 mg/kg
IV 0.003 mg/kg
Group 1

FIG. 1



1
2
3
SC 3 mg/kg
IV 5 mg/kg
IV 3 mg/kg
IV 1 mg/kg
IV 0.3 mg/kg
IV 0.03 mg/kg
IV 0.003 mg/kg
G
F
E
D
C
B
A
Z
Y
X
Day 1
29
57
SC 3 mg/kg
IV 5 mg/kg
IV 1.5 mg/kg

FIG. 2



Cohort B (0.03 mg/kg IV)
Cohort C (0.3 mg/kg IV)
Cohort D (1 mg/kg IV)
Cohort E (3 mg/kg IV)
Cohort F (5 mg/kg IV)
Cohort G (3 mg/kg SC)
LLOQ = 0.05 µg/mL
Serum Drug Conc (µg/mL)
1000
100
10
1
0.1
0.01
0
28
56
84
112
140
168
Time (Day)

FIG. 3



Cohort X (1.5 mg/kg IV q4w x3)
Cohort Y (5.0 mg/kg IV q4w x3)
Cohort Z (3.0 mg/kg SC q4w x3)
Serum Total IgE
Serum Drug Conc (µg/mL)
1000
100
10
1
0.1
0
28
56
84
112
140
168
196
224
Time (Day)

FIG. 4



Day 85
Total IgE (% Change Baseline)
150
100
50
0
-50
Placebo
0.003 mg/kg IV
0.03 mg/kg IV
0.3 mg/kg IV
1 mg/kg IV
3 mg/kg IV
5 mg/kg IV
3 mg/kg SC

FIG. 5A



Day 168
Total IgE (% Change Baseline)
150
100
50
0
-50
Placebo
0.003 mg/kg IV
0.03 mg/kg IV
0.3 mg/kg IV
1 mg/kg IV
3 mg/kg IV
5 mg/kg IV
3 mg/kg SC

FIG. 5B



Placebo IV+SC
MEMP1972A 1.5 mg/kg IV
MEMP1972A 5 mg/kg IV
MEMP1972A 3 mg/kg SC
Total IgE (% Change Baseline)
50
25
0
-25
-50
0
100
200
Days

FIG. 6



Allergen Challenge
Allergen Challenge
Baseline
Wk 12
5 mg/kg IV Anti-M1 Prime
Placebo
Screening
Day -35 to Day -1
Days
1
29
57
5 Months Safety Follow Up
Q4wks for 3 Doses
N=29; Mild Asthmatics

FIG. 7



Day 86 (Week 12)
Placebo (n=13)
MEMP1972A (n=15)
Mean (+/-SE) FEV1 % Pre-challenge
100
90
80
70
0
1
2
3
4
5
6
7
Time from Last Allergen Inhalation (Hrs)

FIG. 8B



Screening
Placebo (n=13)
MEMP1972A (n=15)
Mean (+/-SE) FEV1 % Pre-challenge
100
90
80
70
0
1
2
3
4
5
6
7
Time from Last Allergen Inhalation (Hrs)

FIG. 8A




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 9D




FIG. 10A




FIG. 10B




FIG. 11A




FIG. 11B




FIG. 12A




FIG. 12B



Treatment Period
(36 Weeks)
Follow-up Period
(48 Weeks)
A
MEMP1972A 300 mg SC Monthly x9
B
MEMP1972A 450 mg SC Quarterly x 3 + 1 Additional Dose at Week 4
C
MEMP1972A 150 mg SC Quarterly x 3 + 1 Additional Dose at Week 4
D
Placebo
Wk 0 4 8 12 16 20 24 28 32 36 48 60 72 84
Baseline
Primary Analyses (Week 36)
Study Drug Administration (Active)
Study Drug Administration (Placebo)

FIG. 13




FIG. 14A FIG. 14B

FIG. 14



CH4
Human 200 T K T S G P R A A P E V Y A F A T P E W P G S R D K R T L A C L I Q N F M P E D I S V Q W L H N E V 249
Rhesus 201 T K T S G P R A A P E V Y V F A T P E K L E S R D K R T L A C L I Q N F M P E D I S V Q W L H S D V 250
Cyno 200 T K T S G P R A A P E V Y V F A T P E K L E S R D K R T L A C L I Q N F M P E D I S V Q W L H S D V 249
CH4
Human 250 Q L P D A R H S T T Q P R K T K G S G F F V F S R L E V T R A E W E Q K D E F I C R A V H E A A S P 299
Rhesus 251 Q L P D A R H S V T Q P R K T K G S G F F V F S R L E V T K A E W E Q K D E F I C R A V H E A A S P 300
Cyno 250 Q L P D A R H S V T Q P R K T K G S G F F V F S R L E V T K A E W E Q K D E F I C R A V H E A A S P 299
CH4
M1'
Human 300 S Q T V Q R A V S V N P G L A G G S A Q S Q R A P D R V L C H S G Q Q Q G L P R A A G G S V P H P R 349
Rhesus 301 S W I V Q Q A V S V N P G L A G G S A Q S Q R A P D R V L C H S E Q Q Q G L P R A A R G S V P D H H 350
Cyno 300 S W I V Q Q A V S V N P G L A G G S A Q S Q R A P D R V L C H S E Q Q Q G L P R A A R G S V P D H R 349
M1'
Human 350 C H C G A G R A D W P G P P E L D V C V E E A E G E A P W T W T G L C I F A A L F L L S V S Y S A A 399
Rhesus 351 C H C G A G R A D W P G L P E L D L C V E E A E S E V L W T W T G L C I F A T L F L L S V S Y S A A 400
Cyno 350 C H C G A G R A D W P G L P E L D L C V E E A E S E V L W T W T G L C I F A T L F L L S V S Y S A A 399
Transmembrane Domain
Human 400 L T L L M V Q R F L S A T R Q G R P Q T S L D Y T N V L Q P H A 431
Rhesus 401 I T L L M V Q R F L S A T R Q G R P Q T S L D Y T N V L Q P H A 432
Cyno 400 I T L L M V Q R F L S V T R Q G R P Q T S L D Y T N I L Q P H A 431
T.M.
Intracellular Domain

FIG. 14B



26A11 - VL
Kabat - CDR L1
Chothia - CDR L1
Contact - CDR L1
Kabat - CDR L2
Chothia - CDR L2
Contact - CDR L2
Kabat - CDR L3
Chothia - CDR L3
Contact - CDR L3
Kabat#
huKI
mu26A11
hu26A11.v1,4
hu26A11.v2,5
hu26A11.v3,6
hu26A11.v13,15
hu26A11.v14,16
hu26A11.v1-16

FIG. 15A



7A6 - VL
Kabat#
huKl
mu7A6
hu7A6.v1
Kabat - CDR L1
Chothia - CDR L1
Contact - CDR L1
Kabat - CDR L2
Chothia - CDR L2
Contact - CDR L2
Kabat - CDR L3
Chothia - CDR L3
Contact - CDR L3

FIG. 15B



47H4 - VL
Kabat - CDR L1
Chothia - CDR L1
Contact - CDR L1
Kabat - CDR L2
Chothia - CDR L2
Contact - CDR L2
Kabat - CDR L3
Chothia - CDR L3
Contact - CDR L3
Kabat#
huKI
mu47H4
hu47H4.v1,3
hu47H4.v2,4-6
hu47H4.v1-6

FIG. 15C



26A11 - VH
Kabat#
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41
Kabat - CDR H1
Chothia - CDR H1
Contact - CDR H1
humIII E V Q L V E S G G G L V Q P G G S L R L S C A A S G F T F S S Y A M S W V R Q A P
mu26A11 E V Q L Q Q S G P E L V K P G A S V K M S C K A S G Y T F T D Y Y M M W V K Q S H
hu26A11.v1-3,13,14 E V Q L V E S G G G L V Q P G G S L R L S C A A S G Y T F T D Y Y M M W V R Q A P
hu26A11.v4-6,15,16 E V Q L V E S G G G L V Q P G G S L R L S C A A S G Y T F T D Y Y I M W V R Q A P
Kabat#
42 43 44 45 46 47 48 49 50 51 52 a 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80
Kabat - CDR H2
Chothia - CDR H2
Contact - CDR H2
humIII G K G L E W V S V I S G D G G S T Y Y A D S V K G R F T I S R D N S K N T L Y L
mu26A11 G K S L E W I G D I N P N N Y D T S Y N Q K F K G K A T L T V D K S S S T A Y I
hu26A11.v1-16 G K G L E W V G D I N P N N Y D T S Y N Q K F K G R F T I S A D T S K N T A Y L
Kabat#
81 82 A B C 83 84 85 86 87 88 89 90 91 92 93 94 95 ... ... 101 102 103 104 105 106 107 108 109 110 111 112 113
Kabat - CDR H3
Chothia - CDR H3
Contact - CDR H3
humIII Q M N S L R A E D T A V Y Y C A R G F D Y W G Q G T L V T V S S
mu26A11 Q L N S L T S E D S A V Y Y C A S K A Y W G Q G T L V T V S S
hu26A11.v1-16 Q M N S L R A E D T A V Y Y C A S K A Y W G Q G T L V T V S S

FIG. 15D



7A6 - VH
Kabat - CDR H1
Chothia - CDR H1
Contact - CDR H1
Kabat - CDR H2
Chothia - CDR H2
Contact - CDR H2
Kabat - CDR H3
Chothia - CDR H3
Contact - CDR H3
Kabat#
humIII
mu7A6
hu7A6.v1

FIG. 15E



47H4 - VH
Kabat - CDR H1
Chothia - CDR H1
Contact - CDR H1
Kabat - CDR H2
Chothia - CDR H2
Contact - CDR H2
Kabat - CDR H3
Chothia - CDR H3
Contact - CDR H3
Kabat#
humIII
mu47H4
hu47H4.v1,2,6
hu47H4.v3-5
hu47H4.v1-16
hu47H4.v1,2,5
hu47H4.v3-4,6

FIG. 15F



Percent of Baseline of Challenge Specific IgE (kU/L)
350
250
200
150
200
80
50
S1
0
29
57
85
113
141
169
197
Days
Mean+/-SE Placebo
Mean+/-SE MEMP1972A
Median Placebo
Median MEMP1972A

FIG. 16A



Percent of Baseline of Non-challenge Specific IgE (kU/L)
200
150
100
80
50
S1
0
29
57
85
113
141
169
197
Days
Mean+/-SE Placebo
Mean+/-SE MEMP1972A
Median Placebo
Median MEMP1972A

FIG. 16B